SK284378B6 - Použitie protilátkovej molekuly, ktorá sa viaže na aminokyselinovú sekvenciu WFGNRWHEGYR, na výrobu liečiva na liečenie karcinómov skvamóznych buniek - Google Patents

Použitie protilátkovej molekuly, ktorá sa viaže na aminokyselinovú sekvenciu WFGNRWHEGYR, na výrobu liečiva na liečenie karcinómov skvamóznych buniek Download PDF

Info

Publication number
SK284378B6
SK284378B6 SK736-98A SK73698A SK284378B6 SK 284378 B6 SK284378 B6 SK 284378B6 SK 73698 A SK73698 A SK 73698A SK 284378 B6 SK284378 B6 SK 284378B6
Authority
SK
Slovakia
Prior art keywords
antibody
lymph node
node metastasis
larynx
tumor
Prior art date
Application number
SK736-98A
Other languages
English (en)
Slovak (sk)
Other versions
SK73698A3 (en
Inventor
Karl-Heinz Heider
G�Nther Adolf
Elinborg Ostermann
Erik Patzelt
Marlies Sproll
Original Assignee
Boehringer Ingelheim International Gmbh
Forschungszentrum Karlsruhe Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from DE19545472A external-priority patent/DE19545472A1/de
Application filed by Boehringer Ingelheim International Gmbh, Forschungszentrum Karlsruhe Gmbh filed Critical Boehringer Ingelheim International Gmbh
Publication of SK73698A3 publication Critical patent/SK73698A3/sk
Publication of SK284378B6 publication Critical patent/SK284378B6/sk

Links

Classifications

    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04Organic compounds
    • A61K51/08Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/10Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
    • A61K51/1027Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody against receptors, cell-surface antigens or cell-surface determinants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70585CD44
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2884Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against CD44
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2123/00Preparations for testing in vivo
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/30Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Biophysics (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Physics & Mathematics (AREA)
  • Genetics & Genomics (AREA)
  • Cell Biology (AREA)
  • Optics & Photonics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Hospice & Palliative Care (AREA)
  • Oncology (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biotechnology (AREA)
  • Toxicology (AREA)
  • Microbiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Food Science & Technology (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
SK736-98A 1995-12-06 1996-12-05 Použitie protilátkovej molekuly, ktorá sa viaže na aminokyselinovú sekvenciu WFGNRWHEGYR, na výrobu liečiva na liečenie karcinómov skvamóznych buniek SK284378B6 (sk)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
DE19545472A DE19545472A1 (de) 1995-12-06 1995-12-06 Verfahren zur Diagnose und Therapie von Plattenepithelkarzinomen
DE19615074 1996-04-17
PCT/EP1996/005448 WO1997021104A1 (de) 1995-12-06 1996-12-05 Verfahren zur diagnose und therapie von plattenepithelkarzinomen

Publications (2)

Publication Number Publication Date
SK73698A3 SK73698A3 (en) 1999-01-11
SK284378B6 true SK284378B6 (sk) 2005-02-04

Family

ID=26020988

Family Applications (1)

Application Number Title Priority Date Filing Date
SK736-98A SK284378B6 (sk) 1995-12-06 1996-12-05 Použitie protilátkovej molekuly, ktorá sa viaže na aminokyselinovú sekvenciu WFGNRWHEGYR, na výrobu liečiva na liečenie karcinómov skvamóznych buniek

Country Status (26)

Country Link
EP (1) EP0865609B1 (et)
JP (1) JP2000502067A (et)
KR (1) KR100473824B1 (et)
CN (1) CN1151377C (et)
AR (1) AR004360A1 (et)
AT (1) ATE235056T1 (et)
AU (1) AU726704B2 (et)
BG (1) BG62985B1 (et)
BR (1) BR9611901A (et)
CA (1) CA2239709A1 (et)
CO (1) CO4520233A1 (et)
CZ (1) CZ174198A3 (et)
DE (1) DE59610248D1 (et)
DK (1) DK0865609T3 (et)
EE (1) EE03783B1 (et)
ES (1) ES2190484T3 (et)
HK (1) HK1011560A1 (et)
MX (1) MX9804459A (et)
NO (1) NO319903B1 (et)
NZ (1) NZ324314A (et)
PL (1) PL184521B1 (et)
PT (1) PT865609E (et)
SK (1) SK284378B6 (et)
TR (1) TR199801027T2 (et)
UY (1) UY24389A1 (et)
WO (1) WO1997021104A1 (et)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7189397B2 (en) * 1999-10-08 2007-03-13 Arius Research Inc. Cytotoxicity mediation of cells evidencing surface expression of CD44
US20050100542A1 (en) * 1999-10-08 2005-05-12 Young David S. Cytotoxicity mediation of cells evidencing surface expression of CD44
EE200300569A (et) * 2001-05-18 2004-04-15 Boehringer Ingelheim International Gmbh CD44v6-spetsiifilised antikehad
US20030103985A1 (en) 2001-05-18 2003-06-05 Boehringer Ingelheim International Gmbh Cytotoxic CD44 antibody immunoconjugates
US6972324B2 (en) 2001-05-18 2005-12-06 Boehringer Ingelheim Pharmaceuticals, Inc. Antibodies specific for CD44v6
EP1258255A1 (en) * 2001-05-18 2002-11-20 Boehringer Ingelheim International GmbH Conjugates of an antibody to CD44 and a maytansinoid
EP1391213A1 (en) * 2002-08-21 2004-02-25 Boehringer Ingelheim International GmbH Compositions and methods for treating cancer using maytansinoid CD44 antibody immunoconjugates and chemotherapeutic agents
EP1417974A1 (en) * 2002-11-08 2004-05-12 Boehringer Ingelheim International GmbH Compositions and methods for treating cancer using cytotoxic CD44 antibody immunoconjugates and radiotherapy
CA2786337A1 (en) * 2010-02-04 2011-08-11 F. Hoffmann-La Roche Ag A monoclonal antibody to cd44 for use in the treatment of head and neck squamous cell carcinoma
US9218450B2 (en) * 2012-11-29 2015-12-22 Roche Molecular Systems, Inc. Accurate and fast mapping of reads to genome
JP2021519608A (ja) * 2018-02-22 2021-08-12 マルティチュード・インコーポレーテッド 治療抗体およびその使用
WO2023227644A2 (en) 2022-05-25 2023-11-30 Akiram Therapeutics Ab Binding protein

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1995000658A1 (en) * 1993-06-18 1995-01-05 Sirpa Jalkanen COMPOSITIONS AND DIAGNOSTIC METHODS USING MONOCLONAL ANTIBODIES AGAINST CD44v6
US6010865A (en) * 1993-06-22 2000-01-04 Boehringer Ingelheim International Gmbh Process for detecting a variant CD44 gene product
DE4326573A1 (de) * 1993-08-07 1995-02-23 Boehringer Ingelheim Int Durch Exon v5 des CD44-Gens kodierte Polypeptide als Targets für Immuntherapie und Immunszintigraphie von Tumoren
UA58482C2 (uk) * 1994-06-08 2003-08-15 Бьорінгер Інгельхайм Інтернаціональ Гмбх Моноклональне антитіло vff-18 проти сd44v6 і його фрагменти

Also Published As

Publication number Publication date
EP0865609B1 (de) 2003-03-19
AU1177397A (en) 1997-06-27
DE59610248D1 (de) 2003-04-24
MX9804459A (es) 1998-09-30
EE03783B1 (et) 2002-06-17
NO982588D0 (no) 1998-06-05
PL327066A1 (en) 1998-11-23
JP2000502067A (ja) 2000-02-22
CO4520233A1 (es) 1997-10-15
EP0865609A1 (de) 1998-09-23
CN1151377C (zh) 2004-05-26
NO982588L (no) 1998-08-05
CZ174198A3 (cs) 1999-02-17
KR19990071952A (ko) 1999-09-27
PT865609E (pt) 2003-08-29
HK1011560A1 (en) 1999-07-16
CA2239709A1 (en) 1997-06-12
UY24389A1 (es) 2001-10-25
AU726704B2 (en) 2000-11-16
ES2190484T3 (es) 2003-08-01
CN1207811A (zh) 1999-02-10
EE9800164A (et) 1998-12-15
NZ324314A (en) 2000-02-28
KR100473824B1 (ko) 2005-09-30
WO1997021104A1 (de) 1997-06-12
BR9611901A (pt) 1999-03-02
BG102513A (en) 1999-02-26
BG62985B1 (bg) 2000-12-29
ATE235056T1 (de) 2003-04-15
AR004360A1 (es) 1998-11-04
PL184521B1 (pl) 2002-11-29
TR199801027T2 (xx) 1998-10-21
DK0865609T3 (da) 2003-06-23
SK73698A3 (en) 1999-01-11
NO319903B1 (no) 2005-09-26

Similar Documents

Publication Publication Date Title
CA2563735C (en) Antibodies and molecules derived therefrom that bind to steap-1 proteins
EP1648510B1 (en) Rg1 antibodies and uses thereof
US20030018171A1 (en) High affinity humanized anti-CEA monoclonal antibodies
KR20050059220A (ko) 인간화된 항-과립구 mn-3 항체 및 이들의 용도
AU2007218962A1 (en) Cytotoxicity mediation of cells evidencing surface expression of TROP-2
WO2005032454A2 (en) Anti-muc-1 single chain antibodies for tumor targeting
CZ359196A3 (en) Antibodies, their use and hybridoma cellular line
SK284378B6 (sk) Použitie protilátkovej molekuly, ktorá sa viaže na aminokyselinovú sekvenciu WFGNRWHEGYR, na výrobu liečiva na liečenie karcinómov skvamóznych buniek
BRPI0809351A2 (pt) Anticorpo de anti cd166 humano ligando células tumorais humano
US6372441B1 (en) Method for diagnosis and therapy of Hodgkin's lymphomas
BR122018073034B1 (pt) Anticorpos e moléculas relacionadas que se ligam à proteínas de psca
CA2168988A1 (en) Polypeptides coded by exon v5 of the cd44 gene as targets for immunotherapy and immunoscintigraphy of tumours
AU752494B2 (en) High affinity humanized ANTI-CEA monoclonal antibodies
RU2193779C2 (ru) Средство и способ лечения плоскоклеточного рака
Tang et al. Evaluation of human major histocompatibility complex class I chain-related A as a potential target for tumor imaging
MXPA99005544A (es) Molecula de anticuerpo y su empleo para la diagnosis y terapia de linfomas de hodgkin
BRPI0520902B1 (pt) Anticorpo monoclonal ou fragmento de ligação ao antígeno do mesmo que se liga a proteínas psca para diagnóstico de câncer, método para produção dos mesmos, hibridoma, polinucleotídeo, vetor, composição, ensaio para detectar a presença de uma proteína psca e método de detecção de uma proteína psca
JP2011511767A (ja) 細胞傷害性抗癌モノクローナル抗体